IOCDF-aligned care for adolescents and adults
OCD Treatment in Maplewood, NJ
Evidence-based care for obsessive-compulsive disorder across all presentations — contamination, harm, symmetry, intrusive-thought, scrupulosity, somatic. Higher-dose SSRIs at the doses OCD actually needs, clomipramine as a first-line alternative, and coordinated ERP referrals to NJ-licensed specialists. PMHNP-led in Maplewood or via NJ-wide telehealth.
- IOCDF framework-aligned
- Higher-dose SSRI stewardship
- ERP specialist coordination
Understanding OCD
Intrusive thoughts you can’t shake and rituals that don’t fix them.
Obsessive-compulsive disorder is a specific clinical condition defined by the pairing of two features. Obsessions are unwanted, intrusive, distressing thoughts, images, or urges that feel alien to how you see yourself — the more you try to push them away, the more insistent they become. Compulsions are repetitive behaviors or mental acts you feel driven to perform in response to an obsession, typically to reduce distress or prevent a feared outcome you probably know isn’t rational. DSM-5-TR requires that obsessions or compulsions consume more than one hour each day or cause significant functional impact to meet criteria. Roughly 2% of U.S. adults have OCD1; the average gap between symptom onset and first effective treatment is 7–8 years. Most of that gap is shame and misdiagnosis, not lack of treatment options.
OCD is not the colloquial “I’m so OCD about my desk” personality trait people sometimes describe. It is not perfectionism, orderliness, or attention to detail. Obsessions are ego-dystonic — they feel horrifying, not satisfying. The compulsions provide temporary relief at the cost of reinforcing the fear, which is why the cycle gets worse rather than better with time. The good news: OCD is one of the most treatable conditions in psychiatry when the right framework is used. The hard news: many people with OCD receive treatments that don’t work, at doses that don’t work, for less time than they need. This page covers what we actually do, informed by the IOCDF treatment framework and current evidence.
How OCD presents
Contamination, harm, symmetry, scrupulosity, and more.
OCD presents across a range of content themes, and these themes have clinical implications for treatment planning. Contamination OCD is the classic presentation — fear of germs, illness, or substance contamination paired with washing, cleaning, or avoidance rituals. Harm OCD involves intrusive thoughts about hurting yourself or others (often people you love most) — these are among the most distressing presentations precisely because the thoughts feel horrifying to the person having them; harm OCD is associated with no elevated risk of actual violence, though the anguish it produces is severe. Checking OCD involves repetitive checking (doors, stoves, driving routes for having hit someone) driven by fears of responsibility for harm.
Symmetry and ordering OCD centers on things needing to feel “just right” — a specific count, a specific alignment, a specific feeling. Scrupulosity (religious or moral OCD) involves intrusive blasphemous thoughts, moral doubt, or excessive religious-ritual compulsions. Sexual and relationship OCD involves intrusive, distressing doubts about sexual orientation, attraction to partners, or whether a relationship is “right” — again, these thoughts are ego-dystonic and distressing rather than desired. Somatic OCD involves intrusive focus on bodily sensations (swallowing, blinking, breathing awareness). Many patients have mixed presentations that shift over time. ERP and SSRI pharmacotherapy work across presentations, though the specifics of the exposure work are tailored to the content.
Mental compulsionsdeserve explicit mention because they’re often missed. Not all compulsions are visible behaviors. Silent counting, mental reviewing, praying, mental “cancellation” of bad thoughts, and seeking reassurance from loved ones are all compulsions that maintain the OCD cycle. If your compulsions are entirely internal, you still have full OCD that responds to the same treatment framework.
How we diagnose
How we evaluate OCD.
Diagnosis starts with a thorough interview covering symptom content, time consumed, functional impact, prior treatment history, family history, and comorbidity screening. The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) — or the child version (CY-BOCS) for adolescents under 18 — is the gold-standard severity measure; we administer it at intake and repeat it throughout treatment to track progress quantitatively. Scores under 8 are subclinical; 8–15 mild; 16–23 moderate; 24–31 severe; 32–40 extreme. Treatment response is typically defined as a 25–35% reduction in Y-BOCS score or an absolute score below 16. Using a number alongside clinical conversation makes it harder to miss partial responses and easier to decide when to adjust.
The differential matters. OCD overlaps with generalized anxiety disorder (GAD), obsessive-compulsive personality disorder (OCPD — a different condition), body dysmorphic disorder, hoarding disorder, excoriation (skin-picking), trichotillomania (hair-pulling), Tourette’s syndrome, and autism-spectrum presentations. These conditions often co-occur with OCD and sometimes need their own targeted interventions. We map the full picture at evaluation and plan accordingly. Patients with co-occurring depression — common in chronic, severe OCD — are treated for both concurrently rather than in sequence.
Insight — how clearly you recognize that the obsessions are excessive or unrealistic — varies from “good” (most patients) to “poor” to “absent/delusional.” DSM-5-TR includes specifiers for insight level because poorer insight predicts somewhat lower treatment response and may shift the intervention sequencing. For pediatric-onset cases, we also screen for PANDAS and PANS — autoimmune post-streptococcal presentations with abrupt onset and a different treatment pathway that usually involves pediatric infectious-disease or neurology consultation.
First-line treatment
ERP and SSRIs — the IOCDF framework.
The International OCD Foundation, the APA OCD practice consensus, and the majority of current evidence converge on two first-line treatments that work best together. Exposure and Response Prevention (ERP) is the gold-standard psychotherapy — gradual, structured exposure to feared situations or thoughts paired with deliberate non-performance of the compulsion. ERP produces durable benefit in 60–80% of patients who complete an adequate course2. SSRIs (selective serotonin reuptake inhibitors) are the first-line pharmacotherapy, with clomipramine— a tricyclic antidepressant with strong serotonin-reuptake inhibition — as the main alternative when SSRIs don’t work.
For most patients with moderate-to-severe OCD, the combination of ERP plus an SSRI outperforms either alone and is what we aim for. For mild OCD, ERP alone is often sufficient. For patients who decline therapy or can’t access ERP quickly, SSRI monotherapy is a reasonable start. For pediatric OCD, ERP plus fluoxetine or sertraline is the typical starting point, with parental involvement built into the plan.
Teresa is your prescriber and coordinator; ERP is delivered by a specifically trained therapist. ERP training is not universal among CBT therapists — we refer to NJ-licensed specialists with documented ERP training and current openings, rather than assuming any therapist listing “CBT” can do it. ERP done by a non-specialist often doesn’t work and can make people believe ERP itself doesn’t work.
Why OCD SSRI doses are different
Higher doses, longer trials — and why it matters.
This is probably the single most important piece of patient education on this page. OCD requires substantially higher SSRI doses than depression or general anxiety, and the trial needs to be longer before we declare a medication ineffective. Many patients who believe they’ve “tried an SSRI and it didn’t work” were actually never treated at an OCD-adequate dose for an OCD-adequate duration.
The FDA-approved SSRIs for OCD
Fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft) carry FDA approval specifically for OCD. Citalopram (Celexa) and escitalopram (Lexapro) are used widely off-label with strong evidence. All of the SSRIs work through the same core mechanism for OCD and have roughly comparable efficacy at comparable doses; we pick based on side-effect profile, drug interactions, prior response history, and pregnancy status.
Target doses: OCD vs. depression
Typical OCD target doses sit at the higher end of the FDA-approved range: sertraline 150–200 mg (vs. 50–100 mg common for depression), fluoxetine 40–80 mg (vs. 20 mg), paroxetine 40–60 mg (vs. 20 mg), fluvoxamine 200–300 mg, citalopram 40 mg maximum (the FDA cap at 40 mg limits OCD response for some patients), escitalopram 20–30 mg (vs. 10 mg). Under-dosing is one of the most common reasons OCD patients don’t respond to their first SSRI. We titrate with intent — and if your previous SSRI trial topped out at a depression dose, we don’t count it as a failed trial.
Trial duration: 10–12 weeks at target dose
OCD responds more slowly to SSRIs than depression does. Meaningful symptom reduction typically doesn’t emerge until 6–8 weeks at a therapeutic dose, and the full effect often continues to build through week 12. Declaring a medication “ineffective” before 10–12 weeks at an adequate dose is premature. We make the expected timeline explicit at the start so you know to stay the course through the slow early weeks, and we schedule check-ins frequently enough to manage side effects and dose titration but not so frequently that the visits themselves become a source of pressure.
When SSRIs aren’t enough
Clomipramine and augmentation strategies.
Clomipramine (Anafranil)is a tricyclic antidepressant with particularly strong serotonin-reuptake inhibition and is specifically FDA-approved for OCD. It remains arguably the single most effective medication for OCD — some analyses place its effect size above SSRIs — but it is typically used as second-line because it has a harsher side-effect profile (anticholinergic effects, sedation, weight gain, cardiac effects at higher doses, lowered seizure threshold) and requires more cautious monitoring (baseline and periodic EKG, serum levels sometimes). Typical target dose is 150–250 mg. For patients who haven’t responded to 1–2 adequate SSRI trials, or for severe OCD from the start, clomipramine is the first-line alternative.
When SSRIs (or clomipramine) produce partial benefit but not full response, augmentation strategies with evidence include low-dose atypical antipsychotics (risperidone, aripiprazole — the strongest augmentation evidence in OCD, particularly for patients with poor insight or concurrent tics), and less commonly glutamate modulators (N-acetylcysteine has modest evidence; memantine, riluzole, and ketamine remain mostly investigational). Combining SSRIs with other SSRIs or with SNRIs is not standard practice. We sequence augmentation strategies systematically rather than layering medications reflexively.
For truly treatment-resistant OCD — inadequate response to two or more adequate SSRI trials plus clomipramine plus adequate ERP — there are advanced options. Transcranial magnetic stimulation (TMS) is FDA-approved for OCD and available at several NJ-based programs. Deep brain stimulation (DBS) has FDA humanitarian-device exemption for severe treatment-resistant OCD with roughly two-thirds response in well-selected candidates. These are specialist referrals; medication management with us continues in parallel.
Treatments to avoid
What IOCDF does NOT recommend — and why.
The IOCDF treatment guidance and current evidence explicitly list several interventions that are not effective for OCD. This matters because many OCD patients spend years in treatments that don’t work before finding ERP and an adequately dosed SSRI.
EMDR (Eye Movement Desensitization and Reprocessing) is not an effective treatment for OCD.EMDR has strong evidence for PTSD — a different condition — and is often mentioned by well-meaning therapists as a general “trauma and anxiety” intervention. For OCD specifically, the evidence does not support it, and IOCDF does not recommend it. If a clinician is recommending EMDR as your primary OCD treatment, that recommendation is out of step with current practice.
Psychoanalysis and psychodynamic therapy have not demonstrated efficacy for OCD symptoms; they may be useful for co-occurring issues in some patients but are not primary OCD treatment. Hypnotherapy, thought-field therapy, brainspotting, and reiki lack evidence for OCD. General talk therapy or supportive counseling without ERP tends to worsen OCD by providing reassurance — which functions as a compulsion, reinforcing the cycle.
On the medication side: benzodiazepines as monotherapy do not treat OCD (they may reduce short-term anxiety without changing the underlying condition). Antipsychotics as monotherapy do not treat OCD (they have a role as augmentation, not as standalone treatment). Non-serotonergic antidepressants (bupropion, mirtazapine) alone do not effectively treat OCD core symptoms, though they may help co-occurring depression. Herbal supplements, homeopathy, and acupuncture lack evidence for OCD.
Being direct about what doesn’t work is part of honest OCD care. “Evidence-based treatment” should mean something specific.
Other therapy frameworks
ACT, I-CBT, and metacognitive therapy.
ERP remains the gold standard, but a few additional CBT-family approaches have legitimate OCD evidence and are useful when ERP alone isn’t tolerated or hasn’t produced full response. Acceptance and Commitment Therapy (ACT)adapted for OCD de-emphasizes the direct exposure element and focuses on psychological flexibility and values-based living in the presence of intrusive thoughts; it can be a useful alternative for patients who find ERP’s exposure structure overwhelming.
Inference-Based Cognitive Behavioral Therapy (I-CBT) targets the obsessional doubt itself rather than the exposure-extinction pathway, working on the reasoning process by which patients arrive at the obsessional possibility; it has a growing evidence base and a small but dedicated community of I-CBT-trained therapists. Metacognitive Therapy (MCT) focuses on beliefs about thoughts (meta-worry, meta-cognition) rather than the thought content; some evidence for OCD.
For pediatric OCD where the child won’t engage in treatment, SPACE (Supportive Parenting for Anxious Childhood Emotions)works with the parents alone to reduce family accommodation (the well-meaning family behaviors that inadvertently reinforce OCD) and has good evidence. SPACE doesn’t require child participation, which can be a game-changer when the child is treatment-refusing. We refer to trained SPACE providers when appropriate.
Treatment timeline
What to expect over the first six months.
The first visit is 60–90 minutes: diagnostic interview, Y-BOCS, differential, comorbidity screen, and treatment planning. We aim to leave that visit with a working diagnosis, a medication decision, an ERP referral, and a plan for how ERP and medication will run in parallel.
Medication titration runs roughly 4–6 weeks to an adequate target dose; response assessment extends through week 10–12 at that target dose. SSRI side-effect management (GI upset, initial activation, sexual side effects) is ongoing throughout. ERP typically runs 12–20 sessions over 3–5 months when weekly; intensive ERP programs can compress the same work into 2–4 weeks for patients who can’t commit to months of weekly sessions. By month 3, we have clarity on whether the combined plan is working; by month 6, we know whether to continue, augment, or switch.
Maintenance-phase treatment typically continues for 12–24 months after remission before considering a taper; discontinuation sooner than 12 months of stability roughly doubles relapse risk. Some patients remain on long-term maintenance SSRI therapy because the relapse risk off-medication is too high; the decision is individualized and reviewed at each follow-up.
Crisis and safety
When OCD crosses into safety concerns.
Severe OCD is associated with elevated suicide risk — not from the intrusive thoughts themselves (harm-OCD thoughts about harming yourself are not the same as suicidal ideation and carry no evidence of elevated suicidal behavior), but from the cumulative exhaustion, social withdrawal, and co-occurring depression that untreated OCD produces. We screen at intake and throughout treatment and build safety planning in explicitly when indicated.
If you are in crisis right now: call or text 988 (Suicide & Crisis Lifeline) any time, day or night — free, confidential, staffed by trained counselors. If you are in immediate physical danger or unable to keep yourself safe, call 911 or go to the nearest emergency room. In New Jersey, NJ Hopeline (1-855-654-6735) is a state-specific option, and each county has a Psychiatric Emergency Screening Service (PESS) for in-person mobile crisis response. Our clinic is not a 24/7 crisis service; we follow up at the next scheduled visit after any crisis contact and adjust the plan accordingly.
One specific clarification worth making: patients with harm OCD — intrusive thoughts about hurting themselves or others — are often terrified to mention these thoughts because they fear being misinterpreted as homicidal or suicidal. Harm OCD is not suicidal ideation, and it is not a predictor of violence. Telling your clinician about harm obsessions is important; we will treat those thoughts as the OCD symptom they are, not as a threat.
How Teresa works
PMHNP prescribing with ERP coordination.
Teresa is a PMHNP-BC — board-certified Psychiatric Mental Health Nurse Practitioner — with 5years of clinical experience across the major outpatient psychiatric conditions. Her role in OCD care is diagnosis, medication management with the higher-dose SSRI stewardship OCD requires, brief supportive therapy integrated into visits, clomipramine and augmentation decisions when first-line SSRIs don’t produce adequate response, and coordinated referral to NJ-licensed ERP specialists. Teresa does not provide structured ERP directly; that is a specialist skill delivered by trained therapists with current openings.
Initial evaluation is 60–90 minutes. Follow-up cadence is every 2–4 weeks during initial titration, every 4–8 weeks through the first year, and every 2–3 months for stable maintenance. Visits are substantive — 30–45 minutes covering Y-BOCS tracking, medication tolerance and adherence, ERP progress, lifestyle factors (sleep, caffeine, alcohol which can worsen OCD), and any concerning shifts. We coordinate actively with your ERP therapist with your consent; fragmented care is worse care in OCD.
Hybrid telehealth and in-person care can work well. OCD treatment does not have specific telehealth restrictions, and many patients prefer the convenience of video visits for routine medication management. For patients whose OCD involves contamination themes where leaving home is the trigger, telehealth is often what makes treatment accessible. Schedule IV medications (not typical first-line for OCD) can be prescribed via telehealth when appropriate; Schedule II prescribing (rarely indicated for OCD) follows current New Jersey in-person rules.
Fees & Insurance
Transparent pricing. 18 plans listed — verification required.
Know exactly what care costs before you book. Sliding-scale available for out-of-pocket patients; superbills provided for out-of-network reimbursement.
Initial evaluation
$210
~90 minutes
Comprehensive psychiatric intake. History, symptoms, goals, and a shared treatment plan.
Free introductory call
Free
15 minutes · no obligation
A brief call to see if we're a good fit. Ask questions. Decide at your pace.
Follow-up visit
$130
~30 minutes
Ongoing medication management, adjustments, and supportive care as needed.
18 plans listed
Insurance directories can lag behind actual credentialing status. We verify your specific plan and benefits during the free 15-minute consultation before any paid visit. If your plan isn't listed, ask about a superbill for possible out-of-network reimbursement.
- Aetna
- Anthem
- Blue Cross
- Blue Shield
- BlueCross and BlueShield
- Cigna and Evernorth
- Empire Blue Cross Blue Shield
- Horizon Blue Cross and Blue Shield
- Medicaid
- Meritain Health
- Omnia Tier 1
- Oscar Health
- United Health Oscar Plans
- United Medical Resources (UMR)
- United Medicare
- United NJ Exchange
- United Oxford Medicare
- UnitedHealthcare UHC | UBH
Listed plans last reviewed 2026-05-01.
Payments accepted · Cash · Check · Discover · Mastercard · Visa · Zelle
Sliding scale: Sliding-scale rates are available for self-pay patients. Reductions range from 20% to 50% based on your situation. Discuss during your free 15-minute consultation — no formal paperwork required.
Cancellations: We require 24 hours' notice for cancellations. Missed appointments or late cancellations incur a $75 fee. First-time occurrences are typically waived.
Locations
Serving 9 additional NJ towns
In-person visits at our Maplewood, NJ office, with telehealth available for New Jersey residents when clinically appropriate.
Common questions
Things patients ask about OCD treatment.
Is OCD just being a perfectionist?
No. The colloquial 'I'm so OCD about my desk' pattern is a personality feature (sometimes obsessive-compulsive personality disorder — a different diagnosis) where the preferences feel consistent with who the person is. Clinical OCD is the opposite: intrusive thoughts that feel alien and horrifying, ritual behaviors performed to reduce distress rather than to get satisfaction, time consumption over one hour per day or clear functional impact, and a feeling of being trapped rather than organized. OCD is one of the most treatable psychiatric conditions when the right framework (ERP plus adequately dosed SSRIs) is used — but it almost never looks like tidiness.
Will I need to take SSRIs forever?
For some patients, long-term maintenance is the right call; for others, tapering after extended stability works. Current guidelines recommend continuing SSRI treatment at least 12–24 months after meaningful remission before considering a taper, and longer for patients with multiple prior episodes or very severe baseline OCD. Discontinuation sooner than 12 months of stability roughly doubles relapse risk. When we do taper, we go slowly — typically reducing the dose every 4–8 weeks and watching closely for early symptom re-emergence so we can pause or restart if needed. For patients who remit on ERP plus SSRI and then maintain gains with ongoing ERP skills alone, eventual medication discontinuation is realistic. For others, long-term maintenance is preferable to cycling on and off.
Why do OCD SSRI doses have to be so high?
OCD needs higher SSRI doses than depression — this is probably the single most important piece of OCD pharmacology. Typical OCD targets: sertraline 150–200 mg (vs. 50–100 mg for depression), fluoxetine 40–80 mg (vs. 20 mg), paroxetine 40–60 mg (vs. 20 mg), fluvoxamine 200–300 mg, escitalopram 20–30 mg. Many patients who've 'tried an SSRI and it didn't work' were actually never treated at an OCD-adequate dose. OCD also needs a longer trial — 10–12 weeks at the target dose before declaring a medication ineffective, vs. 6–8 weeks for depression. Under-dosing and premature switching are the most common reasons first-line OCD pharmacotherapy fails.
Can you do ERP with me directly?
Teresa doesn't provide structured ERP directly. ERP is a specialist psychotherapy that requires specific training, a structured protocol, and in many cases in-session or between-session exposure work that doesn't fit the medication-management visit structure. What Teresa does: diagnosis, medication management at adequate OCD doses, brief supportive therapy integrated into visits, and active coordination with a NJ-licensed ERP specialist. When we refer, we refer to therapists with documented ERP training — not general CBT therapists — because ERP done by a non-specialist often doesn't work and sometimes makes patients believe ERP itself is ineffective.
Why doesn't EMDR help OCD?
EMDR is an effective treatment for PTSD, where the evidence is strong. For OCD specifically, EMDR does not have evidence of efficacy, and the International OCD Foundation does not recommend it. The core mechanism of OCD treatment — whether ERP, SSRIs, or both — is disrupting the obsession-compulsion cycle so the feared consequence doesn't drive the ritual, and extinction learning replaces the conditioned avoidance. EMDR's reprocessing mechanism addresses trauma-encoded memories, which is not the central pathology in OCD. If a clinician is recommending EMDR as your primary OCD treatment, that recommendation is out of step with current practice, and we'd suggest a second opinion before committing to a lengthy EMDR course.
What if my OCD is about scary intrusive thoughts (harm, sexual, religious)?
Harm OCD, sexual/relationship OCD, and scrupulosity (religious/moral OCD) are among the most distressing OCD presentations precisely because the intrusive thoughts feel horrifying to the person having them. They are also among the most commonly under-diagnosed presentations, because patients are often too ashamed to mention the thought content. A critical piece of clinical fact: these intrusive thoughts are ego-dystonic (they feel wrong and alien, not desired) and carry no evidence of elevated risk of actual harmful behavior — harm OCD patients are not at elevated risk of violence; sexual OCD patients are not at elevated risk of problematic behavior. ERP adapted for these presentations (with exposure to the feared thought content itself) works well. Naming the intrusive thoughts honestly at your first visit is the first step.
What's the Y-BOCS and why does it matter?
The Yale-Brown Obsessive Compulsive Scale is the gold-standard severity measure for OCD — a structured interview/self-report instrument producing a score from 0 to 40. Scores under 8 are subclinical; 8–15 mild; 16–23 moderate; 24–31 severe; 32–40 extreme. Treatment response is typically defined as a 25–35% Y-BOCS reduction or a score dropping below 16. We administer the Y-BOCS at intake to establish baseline severity and repeat it throughout treatment so we can see whether medication and ERP are actually moving the needle. Numbers aren't everything — your lived experience anchors the plan — but Y-BOCS catches partial responses and helps make dose-adjustment decisions objective rather than impressionistic.
Can I get TMS for OCD?
Yes, if indicated. Transcranial Magnetic Stimulation is FDA-approved for OCD and available at several New Jersey-based programs. TMS is typically considered after inadequate response to two or more adequate SSRI trials plus clomipramine plus adequate ERP — in other words, after standard first- and second-line care has been given a real chance. We don't provide TMS in-house; we refer to programs we trust and continue medication management with you in parallel. Deep brain stimulation (DBS) is a further option for severe treatment-resistant OCD and is available at a very small number of academic programs — it's a significant intervention reserved for patients who haven't responded to everything else.
Can my child with OCD be helped by parent coaching (SPACE)?
SPACE — Supportive Parenting for Anxious Childhood Emotions — is a parent-based intervention developed at Yale for childhood anxiety and OCD that works with the parents alone, without requiring child participation. Its mechanism is reducing family accommodation: the well-meaning behaviors families do to reduce a child's distress (providing reassurance, adjusting schedules, participating in rituals, avoiding triggers) that inadvertently reinforce the OCD cycle. SPACE has good evidence and is particularly useful when the child is treatment-refusing — which is common in pediatric OCD. We see patients ages 12 and older, so SPACE is typically relevant for adolescents; for younger children (under 12), we refer to child-focused programs. We coordinate with NJ-based SPACE-trained providers when appropriate.
Is telehealth OK for OCD treatment?
Yes, when clinically appropriate. Medication management for OCD and ERP delivered by trained therapists can both work by telehealth. For patients whose OCD involves contamination themes where leaving home is itself a trigger, or for patients whose rituals create scheduling pressure, telehealth can be what makes treatment accessible. Schedule IV medications can be prescribed via telehealth when federal and state rules are met; Schedule II prescribing, rarely indicated for OCD, follows New Jersey's in-person requirements.
Ready to stop feeding the cycle?
OCD is one of the most treatable conditions in psychiatry when the right framework is used at the right dose for the right duration. The free 15-minute call is a low-pressure first step.